Business Context and Reporting Period
Company: Accuray Incorporated
Filing Type: Form 8-K (Current Report)
Date of Report: January 12, 2015
Reporting Period: Preliminary estimated results for the quarter ended December 31, 2014 (Second Fiscal Quarter of 2015).
Key Financial Metrics
The filing provides preliminary estimates for the quarter ended December 31, 2014. Specific profit, cash flow, margin, debt, and liquidity figures are not disclosed in this text.
- Total Revenue: Expected to exceed $97 million.
- Gross Orders: Approximately $72 million.
- Net Orders: Approximately $41 million.
- Backlog Change: Net decrease of approximately $6 million (1.7%).
- Order Composition: 28% TomoTherapy (single/dual vault); 26% large university teaching hospitals (non-US/Western Europe); 62% non-university affiliated hospitals; 9% trade-in/trade-up.
Material Changes and Drivers
Revenue is projected to increase 4% year-over-year (7% on a constant currency basis) and 18% sequentially from the first quarter of fiscal 2015. Key drivers and adjustments include:
- Age-outs: Approximately $18 million (as expected).
- Cancellations: Approximately $7 million with no competitive losses.
- Foreign Currency Impact: Approximately $6 million.
- China Market: The Chinese NHFPC issued 6 licenses for Accuray products in the prior month. One system order moved to backlog in Q2 FY15; two are expected in Q3 or Q4 FY15; three pertain to distributor orders already in backlog.
Guidance, Outlook, and Risks
Outlook: The Company expects to release full second-quarter financial results on Tuesday, January 27, 2015, after market close, followed by a conference call webcast at 1:30 p.m. PST.
Risks and Contingencies: The filing includes a Safe Harbor statement noting that actual results could differ materially from preliminary estimates due to the completion of financial reporting processes and review. Additional risks are referenced in the Company's Form 10-K for the fiscal year ended June 30, 2014.
Investor Verification Checklist
- Verify the final audited revenue and profit figures when the full Q2 FY15 results are released on January 27, 2015.
- Confirm the final backlog balance and the specific timing of the two Chinese system orders expected in Q3/Q4 FY15.
- Review the detailed breakdown of the $7 million in cancellations to ensure no competitive losses occurred as stated.
- Assess the impact of the $6 million foreign currency fluctuation on future quarters.